Diabetic Macular Edema

TER regimen with ranibizumab improves retinal anatomy over 24 months in DME

Posted on

Significantly improvements in visual acuity and retinal anatomical structure over the course of 2 years were seen in patients with diabetic macular edema (DME) following a treat and extend regimen (TER) without loading dose under ranibizumab, according to a study.

In this retrospective study, 118 eyes of 87 patients were analyzed for 24 months after the initiation of TER.

During the first and second year, a mean of 9.742.13 injections and 7.632.29 injections, respectively, were applied. From baseline to month 12 and 24, there were significant gains of BCVA and reductions in central retinal thickness. From a baseline of15.3%, the percentage of eyes with an intact inner-/outer segment (IS/OS) junction increased to 42.1% after 2 years. Eyes at baseline that had an intact IS/OS junction increased the probability of having a dry retina after 12 months by 79.3% and after 24 months by 88.1%, and those with less IS/OS disruption baseline predicted longer maximum recurrence-free treatment intervals at 2 years and better BCVA at 1 year.

Bigger intraretinal cysts at baseline was associated with more IS/OS disruption at 2 years. Patients who were younger and those who had lower BCVA at baseline were linked with a higher BCVA gain at 24 months

Giannakaki-Zimmermann H, Behrndt A, Hoffmann L, et al. Predictors for 2-year functional and morphological outcomes of a treat and extend regimen with ranibizumab in patients with diabetic macular edema. Ophthalmic Res. 2021; https://doi.org/10.1159/000514721.

Related Articles
Wearable collision warning device helps visually impaired individuals
Jul 22, 2021
Psoriasis linked with significantly higher risk of retinal diseases
Jul 20, 2021
Ranibizumab biosimilar has comparable efficacy, safety profile to reference product in patients with nAMD
Jul 19, 2021